Nephros, Inc., announced today that Malcom Persen has been appointed to the Board of Directors and as the Chair of the Audit Committee of the commercial stage medical device company. The Company develops and sells high performance liquid purification ultrafilters and an on-line, mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients.
As of right now, Mr. Persen is the Presdent of a solar construction firm he founded in 2011, known as Resolute Performance Contracting. He was the Executive Vice President at Ironco Enterprises from 2009 through 2011. From 2004 through 2008, he served as the CFO for Radyne Corporation, a NASDAQ-traded manufacturer and distributor of satellite and telecommunications equipment. While at Radyne, he participated with the rest of the management team that tripled revenues and sold the firm, resulting in a 100% return for shareholders. Earlier, Mr. Persen was employed as Group Financial Officer for Avnet, Inc., a global distributor of electronic components and computer systems.
Other experiences include assignments with consultancies Arthur D. Little and Mercer Management Consulting. In addition, Mr. Persen lectured in finance at the University of Arizona from 2010 to 2013 and at Boston College from 1988 to 1999. Mr. Persen currently serves on the Board of Valutek, a supplier of cleanroom supplies through direct and distribution channels. Mr. Persen holds a BA in Political Economics from The Colorado College, and an MBA from the Amos Tuck School of Business at Dartmouth College.
“We are excited to have Malcolm join our Board of Directors,” said Daron Evans, CEO of Nephros. “Malcolm’s financial acumen will serve us well as the Chairman of the Audit Committee, and his experience in companies with complex distribution and logistics will serve us well as we seek to expand our customer base and product line.”
“I welcome the opportunity to join the Board of Nephros during this exciting time,” said Mr. Persen. “Nephros’ unique technology platform provides a tremendous opportunity for growth as the company builds its business.”
About Nephros, Inc.
Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with end stage kidney disease. Its filters, which it calls ultrafilters, are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood.
Nephros was founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize a hemodiafiltration system, an alternative method to hemodialysis. Since its founding, the company has extended its filtration technologies to meet the demand for liquid purification in other areas, in particular water purification.
For more information about Nephros and its products, please visit the company’s website atwww.nephros.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the commercialization of Nephros’ HydraGuard products and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.’s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2014. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.
OTCBB closing price for NEPH-L Date: 2015/05/07 Closing Price: 0.79